Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from the FRENVEX group

Vincent Jachiet, Olivier Kosmider, Maxime Beydon, Jerome Hadjadj, Lin-Pierre Zhao, Vincent Grobost, Valentin Lacombe, Guillaume Le Guenno, Yann Nguyen, Jean Benoit Arlet, Jeremie Dion, Mael Heiblig, Alice Garnier, Maxime Samson, Achille Aouba, Sylvain Thepot, Sophie Dimicoli-Salazar, Fabien Dutasta, Benoit Faucher, Estibaliz Lazaro, Pr, Veronique Morel, Antoine Neel, Roderau Outh, Holy Bezanahary, Julien Rossignol, Anne-Sophie Alary, Audrey Bidet, Pauline Blateau, Anne Bouvier, Guilaine Boursier, Matthieu Decamp, Benjamin Lebecque, Yannick Le Bris, Pierre Sujobert, Alice Marceau-Renaut, Cedric Pastoret, David Rizzo, Nathalie Boiret-Dupré, Lara Boucher, Stéphanie Dulucq, Franck Genevieve, Cassandra Jadeau, Pierre Lemaire, Romain Vazquez, Jean Baptiste Rieu, Olivier Fain, Sophie Anne Georgin-Lavialle, Pr, Lucie Rigolot, Lise Larcher, Pierre Hirsch, Benjamin Terrier, Pierre Fenaux, Arsène M Mékinian, Thibault Comont

Blood blood.2024028133.

https://doi.org/10.1182/blood.2024028133

Published: 2025

Includes: Supplemental data

Journal Articles

Vexas Syndrome Is a New Cause of p53-Mediated Erythroblastopenia

François Rodrigues, Giulia Hardouin, Sara El Hoss, Aya Ghoul, Emilie-Fleur Gautier, Michael Dussiot, Sandy Peltier, Pascal Amireault, Annarita Miccio, Vincent Jachiet, Thiago Trovati Maciel, Sophie Georgin Lavialle, Julien Rossignol, Arsène Mekhinian, Olivier Kosmider, Manuel Rodriguez, Olivier Hermine

Blood (2024) 144 (Supplement 1): 36.

https://doi.org/10.1182/blood-2024-208122

Published: 2024

Journal Articles

Diagnosis of mastocytosis: emerging iceberg?

Julien Rossignol, Michel Arock

Blood (2024) 144 (4): 350–352.

https://doi.org/10.1182/blood.2024024943

Published: 2024

Journal Articles

Prognostic Characterization of Advanced Mastocytosis Patients Treated with Midostaurin According to Diagnosis and Mutation-Adjusted Risk Score: A Nation-Wide Ceremast Study of 170 Patients

Mael Heiblig, Clement Gourguechon, Philippe Guilpain, Cristina Bulai Livideanu, Stéphane Barete, Julie Agopian, Fabienne Brenet, Patrice Dubreuil, Richard Lemal, Olivier Tournilhac, Louis Terriou, David Launay, Laurence Bouillet, Gandhi Laurent Damaj, Thomas Ballul, Céline Greco, Laura Polivka, Laurent Frenzel, Cecile Meni, Hassiba Bouktit, Caroline Gaudy-Marqueste, Marie Gousseff, Edwige Le Mouel, Antoine Neel, Dana Ranta, Roland Jaussaud, Thierry Jo Molina, Julie Bruneau, Ludovic Lhermitte, Marie Temple, Olivier Kosmider, Rose-Marie Javier, Fabien Pelletier, Florence Castelain, Frédérique Retornaz, Quentin Cabrera, Patricia Zunic, Marie-Pierre Gourin, Ewa Wierzbicka-Hainaut, Jean-Francois Viallard, Christian Lavigne, Cyrille Hoarau, Isabelle Durieu, Sophie Dimicoli-Salazar, Jose-Miguel Torregrosa-Diaz, Angele Soria, Michel Arock, Christine Bodemer, Olivier Lortholary, Olivier Hermine, Julien Rossignol

Blood (2023) 142 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2023-185890

Published: 2023

Journal Articles

Azacitidine for Patients with Vexas Syndrome: Data from the French Vexas Registry

Thibault Comont, Olivier Kosmider, Mael Heiblig, Benjamin Terrier, Didier Bouscary, Guillaume Le Guenno, Roderau Outh, Maxime Samson, Achille Aouba, Estibaliz Lazarro, Odile Rauzy, Lucie Rigolot, Pierre Peterlin, Alexandre Maria, Edouard Flammarion, Alice Garnier, Benoit De Renzis, Shanti Natarajan, Benjamin Carpentier, Marielle Roux-Sauvat, Jose Torregrosa, Fabienne Closs-Prophette, Julien Rossignol, Nicolas Schleinitz, Celine Dieval, Jonahan Broner, Marie-Pierre Gourin, Gaetan Sauvetre, Benoit Faucher, Julien Vinit, Sylvie Grosleron, Alexis Mathian, Louis Terriou, Cyrille Coustal, Philippe Guilpain, Paola Marianetti-Guingel, Holy Bezanahary, Norbert Vey, Bilal Mohty, Thomas Moulinet, Vincent Grobost, Sophie Dimicoli, Benoit Suzon, Antoinette Perlat, Pierre Hirsh, Lise Larcher, Lin Pierre Zhao, Sophie Georgin-Lavialle, Arsene Mekinian, Pierre Fenaux, Vincent Jachiet, French VEXAS study group, Minhemon French Network of immune disorders associated with hemopathies, GFM Groupe Francophone des Myélodysplasies

Blood (2023) 142 (Supplement 1): 4604.

https://doi.org/10.1182/blood-2023-178125

Published: 2023

Journal Articles

Frequent Alterations of Driver Genes in Chromosome X and Their Clinical Relevance in Extranodal NK/T-Cell Lymphoma

Yuta Ito, Amira Marouf, Yasunori Kogure, Junji Koya, Mariko Tabata, Yuki Saito, Sumito Shingaki, Mitsuhiro Yuasa, Kentaro Yamaguchi, Julie Bruneau, Manon Vavasseur, Michaël Dussiot, Isabelle Andre, Akshay Joshi, Chantal Lagresle-Peyrou, Aude Magerus, Sammara Chaubard, David Lavergne, Emmanuel Bachy, Erika Brunet, Virginie Fataccioli, Chantal Brouzes, Camille Laurent, Laurence De Leval, Alexandra Traverse-Glehen, Céline Bossard, Marie Parrens, Véronique Meignin, Laure Philippe, Julien Rossignol, Felipe Suarez, Jean-Marie Michot, Olivier Tournilhac, Christine Bole-Feysot, Patrick Nitschke, Bruno Tesson, Cécile Laurent, Thierry Jo Molina, Vahid Asnafi, Sachiko Tsukita, Koji Izutsu, Hiroaki Miyoshi, Seiji Sakata, Akito Dobashi, Kengo Takeuchi, Koichi Ohshima, Philippe Gaulard, Arnaud Jaccard, Seishi Ogawa, Olivier Hermine, Keisuke Kataoka, Lucile Couronne

Blood (2022) 140 (Supplement 1): 1737–1739.

https://doi.org/10.1182/blood-2022-159869

Published: 2022

Journal Articles

Azacitidine (AZA) for Patients with Vexas and Myelodysplastic Syndrome (MDS): Data from the French Vexas Registry

Thibault Comont, Maël Heiblig, Jeremie Dion, Etienne Riviere, Louis Terriou, Julien Rossignol, Virginie Rieu, Guillaume Le Guenno, Alexis Mathian, Achille Aouba, Julien Vinit, Benjamin Terrier, Olivier Kosmider, Sophie Georgin-Lavialle, Pierre Fenaux, Arsene Mekinian

Blood (2021) 138 (Supplement 1): 3689.

https://doi.org/10.1182/blood-2021-152363

Published: 2021

Journal Articles

Molecular Profiling Feasibility on Cell-Free Tumoral DNA in Relapse/Refractory (R/R) Multiple Myeloma (MM) Patients Screened for Phase I Trials

Cyril Quivoron, Helene Lecourt, Jean-Marie Michot, Julien Lazarovici, Julien Rossignol, David Ghez, Veronique Vergé, Veronique Saada, Alina Danu, Vincent Ribrag

Blood (2021) 138 (Supplement 1): 3763.

https://doi.org/10.1182/blood-2021-149369

Published: 2021

Journal Articles

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

Jean-Marie Michot, MD, Valérie Camara-Clayette, PhD, Cyril Quivoron, PhD, Alina Danu, MD, Julien Lazarovici, MD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Clementine Sarkozy, MD PhD, Andrea Varga, MD, Helene Lecourt, Veronique Vergé, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136134

Published: 2020

Journal Articles

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Cyril Quivoron, PhD, Jean-Marie Michot, MD, Valérie Camara-clayette, PhD, Alina Danu, MD, Julien Lazarovici, MD, Clementine Sarkozy, MD PhD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Helene Lecourt, Veronique Vergé, MD, Andrea Varga, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-136114

Published: 2020

Journal Articles

Comparative Study of Tumor Biopsy and Ctdna to Support Patient Selection in Phase I Trials: The Gustave Roussy Single Center Experience in Aggressive B-Cell Lymphomas

Anthony Tarabay, MD, Jean-Marie Michot, MD, Anne Aupérin, Julien Lazarovici, Julien Rossignol, MD PhD, David Ghez, MD PhD, Peggy Dartigues-Cuillères, MD, Veronique Vergé, Vincent Ribrag, MD, Christophe Massard, Valérie Camara-clayette

Blood (2019) 134 (Supplement_1): 1496.

https://doi.org/10.1182/blood-2019-127170

Published: 2019

Journal Articles

BCL-2 Is Expressed in Advanced Mastocytosis and Midaustorin Induces Venetoclax Sensitivity of Mast Leukemia Cell Lines

Danielle Canioni, MD, Josquin Moraly, MD, Ludovic Lhermitte, MD PhD, Laura Polivka, MD, Mélanie Féroul, Julien Rossignol, MD PhD, Laurent Frenzel, MD PhD, Michel Arock, pharmD, PhD, Patrice Dubreuil, PhD, Leila maouche-Chretien, PhD, Olivier Hermine, MD PhD

Blood (2019) 134 (Supplement_1): 1683.

https://doi.org/10.1182/blood-2019-131256

Published: 2019

Journal Articles

Serotonin Targeting Using Common Antidepressants Induces Rapid Recovery of Cytopenia

Tereza Coman, MD PhD, Guillemette Fouquet, Julien Rossignol, MD PhD, Jean-Henri Bourhis, Olivier Hermine, Francine Côté, PhD

Blood (2019) 134 (Supplement_1): 3715.

https://doi.org/10.1182/blood-2019-122658

Published: 2019

Journal Articles

Non-Effectiveness of Using RICE Post RDHAP or RDHAP Post RICE after Failure of First Line Salvage Therapy in DLBCL Patients Who Are Eligible for ASCT

Tony Ibrahim, MD MSc, Tarek Assi, Julien Lazarovici, MD, Maxime Annereau, PharmD, David Ghez, MD PhD, Jean-Marie Michot, MD, Julia Arfi-Rouche, Julien Rossignol, MD PhD, Veronique Vergé, Jacques Bosq, Peggy Dartigues-Cuillères, MD, Alina Danu, MD, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 4226.

https://doi.org/10.1182/blood-2018-99-117444

Published: 2018

Journal Articles

Omalizumab: Efficacy and Safety in Mast Cell Disorders

Richard Lemal, MD, Guillemette Fouquet, Louis Terriou, MD, Mélanie Vaes, MD, Cristina Livideanu, MD, Laurent Frenzel, MD PhD, Stéphane Barete, Danielle Canioni, MD, Ludovic Lhermitte, MD PhD, Jacques-Olivier Bay, MD PhD, Julien Rossignol, MD PhD, Michel Arock, Olivier Lortholary, Olivier Hermine, MD PhD

Blood (2018) 132 (Supplement 1): 4280.

https://doi.org/10.1182/blood-2018-99-114739

Published: 2018

Journal Articles

Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma

Tarek Assi, Jean-Marie Michot, MD, Toni Ibrahim, MD MSc, Fabien Le Bras, Karim Belhadj, Julien Lazarovici, MD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Veronique Vergé, Julia Arfi-Rouche, Sophie Cotteret, Christophe Massard, Jean-Charles Soria, Alina Danu, MD, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 2001.

https://doi.org/10.1182/blood-2018-99-111050

Published: 2018

Journal Articles

Management of Post-Transplant Lymphoproliferative Disorders in the Real Life: The French Attitude Between 2010 and 2013

Inès Boussen, Caroline Algrin, MD, Julien Rossignol, MD, Eric Durot, MD, Sarah Guenounou, Antoine Bonnet, Jeremy Delage, MD, Emmanuel Gyan, MD PhD, Fontanet Bijou, MD, Noel Milpied, MD, Adrien Chauchet, MD, Adrien Tempescul, MD, Gandhi Damaj, MD, Arnaud Jaccard, MD PhD, Jerome Cornillon, MD, Norbert Ifrah, Veronique Leblond, Sylvain Choquet, MD

Blood (2016) 128 (22): 4230.

https://doi.org/10.1182/blood.V128.22.4230.4230

Published: 2016

Journal Articles

XPO1 (Exportin-1) Is a Major Regulator of Human Erythroid Differentiation. Potential Clinical Applications to Decrease Ineffective Erythropoiesis of Beta-Thalassemia

Flavia Guillem, PhD, Michael Dussiot, PhD, Sebastien Causse, PhD, Guillaume Marcion, Emilie-Fleur Gautier, PhD, Julien Rossignol, MD, Jean benoit Arlet, MD PhD, Mathilde Lamarque, MD, Patrick Mayeux, PhD, Frederique Verdier, PhD, Xiuli An, MD PhD, Jean-Antoine Ribeil, MD PhD, Carmen Garrido, PhD, Genevieve Courtois, PhD, Narla Mohandas, D.Sc., Olivier Hermine

Blood (2015) 126 (23): 2368.

https://doi.org/10.1182/blood.V126.23.2368.2368

Published: 2015

Journal Articles

Development of an Anti-HTLV-1 Vaccine for the Treatment of Adult T-Cell Leukemia/Lymphoma

Déborah Revaud, PhD, Ana Bejanariu, PhD, Lamya Loussaief, Emeline Sarry, Abdel Zemmar, Guillaume Deplaine, PhD, Téreza Coman, MD, Julien Rossignol, MD, Olivier Hermine, Cecile Bauche, PhD

Blood (2015) 126 (23): 4010.

https://doi.org/10.1182/blood.V126.23.4010.4010

Published: 2015

Journal Articles

Efficacy of Azacitidine (AZA) in Autoimmune and Inflammatory Disorders (AID) Associated with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Blood (2015) 126 (23): 1695.

https://doi.org/10.1182/blood.V126.23.1695.1695

Published: 2015

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from the FRENVEX group

Vexas Syndrome Is a New Cause of p53-Mediated Erythroblastopenia

Diagnosis of mastocytosis: emerging iceberg?

Prognostic Characterization of Advanced Mastocytosis Patients Treated with Midostaurin According to Diagnosis and Mutation-Adjusted Risk Score: A Nation-Wide Ceremast Study of 170 Patients

Azacitidine for Patients with Vexas Syndrome: Data from the French Vexas Registry

Frequent Alterations of Driver Genes in Chromosome X and Their Clinical Relevance in Extranodal NK/T-Cell Lymphoma

Azacitidine (AZA) for Patients with Vexas and Myelodysplastic Syndrome (MDS): Data from the French Vexas Registry

Molecular Profiling Feasibility on Cell-Free Tumoral DNA in Relapse/Refractory (R/R) Multiple Myeloma (MM) Patients Screened for Phase I Trials

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Comparative Study of Tumor Biopsy and Ctdna to Support Patient Selection in Phase I Trials: The Gustave Roussy Single Center Experience in Aggressive B-Cell Lymphomas

BCL-2 Is Expressed in Advanced Mastocytosis and Midaustorin Induces Venetoclax Sensitivity of Mast Leukemia Cell Lines

Serotonin Targeting Using Common Antidepressants Induces Rapid Recovery of Cytopenia

Non-Effectiveness of Using RICE Post RDHAP or RDHAP Post RICE after Failure of First Line Salvage Therapy in DLBCL Patients Who Are Eligible for ASCT

Omalizumab: Efficacy and Safety in Mast Cell Disorders

Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma

Management of Post-Transplant Lymphoproliferative Disorders in the Real Life: The French Attitude Between 2010 and 2013

XPO1 (Exportin-1) Is a Major Regulator of Human Erythroid Differentiation. Potential Clinical Applications to Decrease Ineffective Erythropoiesis of Beta-Thalassemia

Development of an Anti-HTLV-1 Vaccine for the Treatment of Adult T-Cell Leukemia/Lymphoma

Efficacy of Azacitidine (AZA) in Autoimmune and Inflammatory Disorders (AID) Associated with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only